The role of 18F-sodium fluoride PET/CT bone scans in the diagnosis of metastatic bone disease from breast and prostate cancer

Kulshrestha, R; England, A; Nightingale, JM; Vinjamuri, R; Hogg, P

Abstract

This article shall describe the role of 18F-Sodium Fluoride (18F-NaF) PET/CT bone scanning in the staging of breast and prostate cancer. 18F-NaF PET was initially utilised as a bone scanning agent in the 1960s and early 1970s, however its usage was restricted by the then available gamma cameras. The advent of hybrid PET/CT cameras in the late 1990s has shown a resurgence of interest in its usage and role. After a brief introduction, this paper will describe the radiopharmaceutical properties, dosimetry, pharmacokinetics, and mechanism of uptake of 18F-NaF. The performance of 18F-NaF PET/CT is then compared with conventional bone scintigraphy utilizing current evidence from the literature. Strengths and weaknesses of 18F-NaF PET/CT imaging shall be highlighted. Clinical examples of improved accuracy of diagnosis and impact on patient management shall be illustrated. Limitations of 18F-NaF PET/CT imaging will be outlined.

Citation

Kulshrestha, R., England, A., Nightingale, J., Vinjamuri, R., & Hogg, P. (2016). The role of 18F-sodium fluoride PET/CT bone scans in the diagnosis of metastatic bone disease from breast and prostate cancer. Journal of Nuclear Medicine Technology, 44(4), 217-222. https://doi.org/10.2967/jnmt.116.176859

• Journal Article Type: Article
• Acceptance Date: Aug 15, 2016
• Online Publication Date: Sep 15, 2016
• Publication Date: Sep 15, 2016
• Deposit Date: Sep 1, 2016
• Journal: Journal of Nuclear Medicine Technology
• Print ISSN: 0091-4916
• Electronic ISSN: 1535-5675
• Publisher: Society of Nuclear Medicine
• Volume: 44
• Issue: 4
• Pages: 217-222
• DOI: https://doi.org/10.2967/jnmt.116.176859
• Publisher URL: http://dx.doi.org/10.2967/jnmt.116.176859
• Related Public URLs: http://tech.snmjournals.org/